| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $18,970 | 6 | 100 |
Sells | $0 | 0 | 0 |
| Michel Robert J | Chief Financial Officer | 2 | $9,900 | 0 | $0 | $9,900 |
| Feldschuh Michael Richard | Chief Executive Officer | 1 | $9,070 | 0 | $0 | $9,070 |
| Feldschuh Jonathan Adam | Chief Scientific Officer | 1 | $0 | 0 | $0 | $0 |
| Jefferies John | Chief Medical Officer | 2 | $0 | 0 | $0 | $0 |
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant …
Over the last 12 months, insiders at Daxor Corporation have bought $18,970 and sold $0 worth of Daxor Corporation stock.
On average, over the past 5 years, insiders at Daxor Corporation have bought $49,539 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Michel Robert J (Chief Financial Officer) — $9,900. Feldschuh Michael Richard (Chief Executive Officer) — $9,070.
The last purchase of 1,000 shares for transaction amount of $9,070 was made by Feldschuh Michael Richard (Chief Executive Officer) on 2026‑04‑08.
| 2026-04-08 | Feldschuh Michael Richard | Chief Executive Officer | 1,000 0.0203% | $9.07 | $9,070 | +14.11% | ||
| 2026-03-31 | Michel Robert J | Chief Financial Officer | 1,000 0.0203% | $9.90 | $9,900 | +6.52% | ||
| 2026-03-20 | Jefferies John | Chief Medical Officer | 5,941 – | $0 | $0 | -5.85% | ||
| 2025-12-09 | Feldschuh Jonathan Adam | Chief Scientific Officer | 18,000 – | $0 | $0 | -15.52% | ||
| 2025-12-09 | Michel Robert J | Chief Financial Officer | 3,000 – | $0 | $0 | -15.52% | ||
| 2025-11-12 | Jefferies John | Chief Medical Officer | 2,344 – | $0 | $0 | -16.17% | ||
| 2025-04-04 | Feldschuh Michael Richard | Chief Executive Officer | 2,063 0.044% | $7.89 | $16,277 | +49.02% | ||
| 2025-03-10 | Feldschuh Michael Richard | Chief Executive Officer | 3,360 0.0688% | $7.68 | $25,805 | +46.52% | ||
| 2025-03-10 | Michel Robert J | Chief Financial Officer | 1,000 0.0213% | $8.00 | $8,000 | +46.52% | ||
| 2024-12-06 | Feldschuh Michael Richard | Chief Executive Officer | 45,000 – | $0 | $0 | +1.24% | ||
| 2024-12-06 | Feldschuh Jonathan Adam | Chief Scientific Officer | 32,000 – | $0 | $0 | +1.24% | ||
| 2024-03-27 | Michel Robert J | Chief Financial Officer | 750 0.0161% | $8.70 | $6,525 | +3.15% | ||
| 2024-03-26 | Feldschuh Michael Richard | Chief Executive Office | 1,000 0.0199% | $8.13 | $8,130 | +2.43% | ||
| 2024-03-19 | Feldschuh Michael Richard | Chief Executive Officer | 647 0.0133% | $8.15 | $5,273 | +5.60% | ||
| 2024-03-10 | Feldschuh Michael Richard | Chief Executive Officer | 1,492 0.0308% | $7.72 | $11,518 | +7.52% | ||
| 2024-03-04 | Feuer Edward | director | 1,000 0.0212% | $7.21 | $7,210 | +23.37% | ||
| 2023-12-06 | Michel Robert J | Chief Financial Officer | 120 0.0025% | $7.75 | $930 | +12.14% | ||
| 2023-12-01 | Feldschuh Michael Richard | Chief Executive Officer | 800 0.0166% | $7.80 | $6,240 | +13.63% | ||
| 2023-12-01 | Michel Robert J | Chief Financial Officer | 180 0.0037% | $7.75 | $1,395 | +13.63% | ||
| 2023-11-24 | Michel Robert J | Chief Financial Officer | 500 0.0104% | $7.94 | $3,970 | +12.09% |
| Feldschuh Michael Richard | Chief Executive Officer | 213694 3.6603% | $1.86M | 38 | 1 | +34.09% |
| Feldschuh Jonathan Adam | Chief Scientific Officer | 53908 0.9234% | $468,999.60 | 2 | 1 | |
| Jefferies John | Chief Medical Officer | 23557 0.4035% | $204,945.90 | 2 | 0 | |
| Michel Robert J | Chief Financial Officer | 21050 0.3606% | $183,135.00 | 13 | 0 | +37.17% |
| FELDSCHUH JOSEPH | 10 percent owner | 2774455 47.5223% | $24.14M | 105 | 3 | +24.27% |
| Hudson Philip Nordan | director | 146200 2.5042% | $1.27M | 13 | 0 | |
| WILLENS ROBERT | director | 18164 0.3111% | $158,026.80 | 17 | 0 | +21.24% |
| WOLPOFF MARTIN S | director | 4000 0.0685% | $34,800.00 | 8 | 2 | +18.35% |
| DesRosiers Caleb | director | 3157 0.0541% | $27,465.90 | 1 | 0 | |
| Thompson Soren | VP, Business Development | 1950 0.0334% | $16,965.00 | 2 | 1 | +54.72% |
| MOUSSA ROBERT G | director | 1000 0.0171% | $8,700.00 | 2 | 0 | |
| Feuer Edward | director | 1000 0.0171% | $8,700.00 | 2 | 0 | +30.13% |
| LOMBARD JAMES A | director | 500 0.0086% | $4,350.00 | 1 | 0 | |
| Valentine Stephen | director | 500 0.0086% | $4,350.00 | 1 | 0 | |
| Meegan Diane Marie | Corporate Secretary | 500 0.0086% | $4,350.00 | 1 | 1 | |
| Engstrom Everis | Vice President | 500 0.0086% | $4,350.00 | 1 | 0 | |
| Goudie Joy S. | director | 300 0.0051% | $2,610.00 | 1 | 0 | |
| Saxe Bernhard | director | 200 0.0034% | $1,740.00 | 1 | 0 |
Daxor Corporation (DXR) | $167,495 | 10 | 32.53% | $50.79M |
$8,662,717 | 6 | -49.85% | $7.36M | |
$773,064 | 3 | 25.52% | $7.16B | |
$858,500 | 3 | 13.15% | $1.73B | |
$34,477,719 | 2 | -9.33% | $51.35M |
| Increased Positions | 4 | +50% | 13,091 | +15.46% |
| Decreased Positions | 3 | -37.5% | 1,040 | -1.23% |
| New Positions | 3 | New | 13,090 | New |
| Sold Out Positions | <1 | Sold Out | 40 | Sold Out |
| Total Postitions | 9 | +12.5% | 96,709 | +14.23% |
| Vanguard Group Inc | $704.00 | 0.98% | 49,028 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $415.00 | 0.58% | 28,921 | +900 | +3.21% | 2025-09-30 |
| Morgan Stanley | $51.00 | 0.07% | 3,537 | -18 | -0.51% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $45.00 | 0.06% | 3,128 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $1.00 | <0.01% | 40 | +40 | New | 2025-09-30 |
| Jpmorgan Chase & Co | $0 | 0% | 4 | 0 | 0% | 2025-09-30 |
| Keyes, Stange & Wooten Wealth Management, Llc | $0 | 0% | 0 | -15,914 | Sold Out | 2025-09-30 |